Signed in · PRO

Guidance history, every release

Edwards Lifesciences (EW) · 8 releases, Oct 24, 2024 to Jul 23, 2026 · rows are metrics, columns are releases

Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing

Metric	Oct 24, 2024 FY24 Q3	Feb 11, 2025 FY24 Q4	Apr 23, 2025 FY25 Q1	Jul 24, 2025 FY25 Q2	Oct 30, 2025 FY25 Q3	Feb 10, 2026 FY25 Q4	Apr 23, 2026 FY26 Q1	Jul 23, 2026 FY26 Q2
For FY2026
TMTT revenue	—	—	—	—	—	New“$740 – $780 million”	—	—
TMTT revenue growth	—	—	—	—	—	New“35 – 45% to $740 – $780 million”	—	—
Total sales	—	—	—	—	—	—	—	New“between $1.63 and $1.71 billion”
Total sales	—	—	—	—	—	—	New“between $1.66 and $1.74 billion”	—
Total sales	—	—	—	—	—	New“between $1.55 and $1.63 billion”	—	—
Adjusted EPS	—	—	—	—	—	—	—	New“$2.95 to $3.05”
Adjusted EPS	—	—	—	—	—	—	—	New“$0.71 to $0.77”
Adjusted EPS	—	—	—	—	—	New“$2.90 – $3.05”	Narrowed“$2.95 to $3.05”	—
Adjusted EPS	—	—	—	—	—	—	New“$0.70 to $0.76”	—
Adjusted EPS	—	—	—	—	—	New“$0.70 to $0.76”	—	—
Adjusted EPS growth at midpoint	—	—	—	—	—	—	—	New“17% at midpoint”
Adjusted gross profit margin	—	—	—	—	—	New“between 78% and 79%”	—	—
Constant currency operating margin expansion	—	—	—	—	—	—	New“approximately 150 basis points”	Reiterated“approximately 150 basis points”
EPS	—	—	—	—	—	New“$2.90 to $3.05”	—	—
Gross margin	—	—	—	—	—	—	New“78% to 79%”	—
Gross profit margin	—	—	—	—	—	—	—	New“at the lower end of its full-year 78% to 79%”
Gross profit margin	—	—	—	—	—	—	—	New“lower end of its full-year 78% to 79% gross margin guidance”
Operating profit margin	—	—	—	—	—	—	New“high end of the company’s original 28% to 3 29% guidance range”	Reiterated“high end of the company’s original 28% to 29% guidance range”
Operating profit margin	—	—	—	—	—	New“at the high end of the original 28% to 29% guidance range”	—	—
Constant currency sales growth	—	—	—	—	—	—	New“9% to 11%”	—
Constant currency sales growth	—	—	—	—	—	New“8 – 10%”	—	—
Effective tax rate, excluding special items	—	—	—	—	—	—	—	New“at the high end of its previous range of 16% to 19%”
R&D as a percentage of sales	—	—	—	—	—	New“approximately 17%”	—	—
R&D expense as a percentage of sales	—	—	—	—	—	—	New“approximately 17%”	Reiterated“approximately 17%”
Sales growth rate	—	—	—	—	—	—	New“9% to 11%”	—
Sales growth rate	—	—	—	—	—	New“8 to 10%”	—	—
Structural heart therapies contributions	—	New“Increasing contributions from an expanding set of structural heart therapies”	—	—	—	—	—	—
Surgical sales growth	—	—	—	—	—	—	New“mid-single-digit”	—
TAVR product group sales growth rate	—	—	—	—	—	—	New“7% to 9%”	—
TAVR sales	—	—	—	—	—	—	New“$4.7 to $5.0 billion”	Narrowed“$4.75 billion to $5.0 billion”
TAVR sales growth (constant currency)	—	—	—	—	—	—	—	New“8% to 9%”
TMTT growing	—	—	—	—	—	New“35 – 45%”	—	—
TMTT growth	—	—	—	—	—	New“35 – 45%”	—	—
TMTT product group sales	—	—	—	—	—	—	—	New“$760 to $780 million”
TMTT sales	—	—	—	—	—	New“$740 – $780 million”	Reiterated“$740 to $780 million”	—
Total company sales	—	—	—	—	—	—	—	New“$6.6 billion to $6.9 billion”
Total company sales	—	—	—	—	—	—	New“$6.5 to $6.9 billion”	—
Total company sales growth (constant currency)	—	—	—	—	—	—	—	New“10% to 11%”
For FY2025
Total sales	—	—	—	—	New“$1.51 and $1.59 billion”	—	—	—
Total sales	—	—	—	New“between $1.46 and $1.54 billion”	—	—	—	—
Total sales	—	—	New“$1.45 and $1.53 billion”	—	—	—	—	—
Total sales	—	New“between $1.35 and $1.43 billion”	—	—	—	—	—	—
Adjusted EPS	—	New“$2.40 - $2.50”	Reiterated“$2.40 to $2.50”	—	Raised“$2.56 to $2.62”	—	—	—
Adjusted EPS	—	—	—	—	New“$0.58 to $0.64”	—	—	—
Adjusted EPS	—	—	—	New“high end of its original range of $2.40 to $2.50”	—	—	—	—
Adjusted EPS	—	—	—	New“$0.54 to $0.60”	—	—	—	—
Adjusted EPS	—	—	New“$0.59 to $0.65”	—	—	—	—	—
Adjusted EPS	—	New“$0.58 to $0.64”	—	—	—	—	—	—
Adjusted gross profit margin	—	New“between 78% and 79%”	—	—	—	—	—	—
Adjusted operating margins	—	New“27 to 28%”	—	—	—	—	—	—
Operating margin	—	—	New“27% to 28%”	—	—	—	—	—
Edwards sales growth	—	—	New“8-10%”	—	—	—	—	—
Operational SG&A spending	—	New“approximately flat at these levels”	—	—	—	—	—	—
R&D spending	—	New“maintain R&D spending at these levels”	—	—	—	—	—	—
Sales growth (constant currency)	—	New“8% - 10%”	—	—	—	—	—	—
TAVR sales	—	—	—	New“$4.3 billion to $4.5 billion”	—	—	—	—
TAVR underlying growth rate	—	—	—	New“6% to 7%”	—	—	—	—
TMTT and Surgical sales	—	—	—	New“remains unchanged”	—	—	—	—
TMTT sales	—	—	New“$530 million to $550 million”	—	—	—	—	—
Total company sales	—	—	New“$5.7 to $6.1 billion”	Narrowed“$5.9 billion to $6.1 billion”	—	—	—	—
For FY2024
EPS	New“$0.53 to $0.57”	—	—	—	—	—	—	—
Gross margin	New“in-line with the high end of its 76% to 78% full-year guidance range”	—	—	—	—	—	—	—
Gross margin (full-year)	New“76% to 78%”	—	—	—	—	—	—	—
Sales	New“$1.33 to $1.39 billion”	—	—	—	—	—	—	—
Sales growth	New“8 to 10%”	—	—	—	—	—	—	—
No period stated
Operating profit margin	—	New“annual operating profit margin expansion thereafter”	—	—	—	—	—	—
R&D as a percentage of sales	—	New“moderate R&D as a percentage of sales over time”	—	—	—	—	—	—
SG&A ratio	—	New“lower SG&A ratio over time”	—	—	—	—	—	—
Total company sales growth target, longer term	—	—	—	—	—	—	—	New“approximately 10% total company sales growth, on average”

Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.